Decitabine Based Chemotherapy Followed by Haploidentical Lymphocyte Infusion for Elderly Patients With AML
Status:
Completed
Trial end date:
2019-03-01
Target enrollment:
Participant gender:
Summary
Demethylating agent decitabine enhances the immunogenicity of leukemia cells by inducing the
expression of cancer testis antigens (CTAs),MHC class I and II molecules,costimulatory
molecules and adhesion molecules. The leukemias cells treated by decitabine will become more
sensitive to the following adoptive T cell therapy.We proposed a hypothesis that
decitabine-based chemotherapy acts in synergestic with haploidentical lymphocyte infusion in
eliciting leukemia specific cytotoxic lymphocyte(CTL) and diminishing leukemic cells.